Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17669051 | 0.98 | OPRM1 (0.39) | OPRM1LMNADNM1SMPD1FDPS | |
| SCHEMBL17669034 | 0.91 | DNM1 (0.32) | OPRM1DNM1 | |
| SCHEMBL320815 | 0.82 | — | — | |
| SCHEMBL17669045 | 0.81 | ZDHHC7 (0.37) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL28058809 | 0.81 | TSHR (0.31) | TSHR | |
| SCHEMBL17668935 | 0.78 | OPRM1 (0.36) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL28343743 | 0.78 | OPRM1 (0.41) | OPRM1LMNADNM1TSHRTHRB | |
| SCHEMBL4735091 | 0.77 | OPRM1 (0.44) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL6298297 | 0.77 | OPRM1 (0.44) | OPRM1LMNADNM1SMPD1TSHR | |
| SCHEMBL5574668 | 0.77 | OPRM1 (0.44) | OPRM1LMNADNM1SMPD1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009439-B1 | CYCLIC AMINOORGANOXYSILANE COMPOUND AND ITS PRODUCTION METHOD | SHINETSU CHEMICAL CO (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-9371341-B2 | Cyclic aminoorganoxysilane compound and its production method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-06-21 | — | — | US | disclosed |
| EP-3009439-A1 | CYCLIC AMINOORGANOXYSILANE COMPOUND AND ITS PRODUCTION METHOD | Shin-Etsu Chemical Co., Ltd. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20160102111-A1 | CYCLIC AMINOORGANOXYSILANE COMPOUND AND ITS PRODUCTION METHOD | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102111-A1 | CYCLIC AMINOORGANOXYSILANE COMPOUND AND ITS PRODUCTION METHOD | BCAT2, BCAT1, AKR1B10 | OPRM1 323/4885LMNA 3625/4885DNM1 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.